Islet Function in Gestational Diabetes

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Mayo Clinic
Study ID
NCT07806695
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Gestational Diabetes Mellitus

Eligibility Criteria

Sex
FEMALE
Age
20 Years - 40 Years
Healthy Volunteers
Not accepted

Interventions

  • Exendin 9-39 — DRUG
    Exendin 9-39 will be administered during one postpartum study day as an intravenous infusion at 300 pmol/kg/min for 4 hours, beginning 60 minutes before the graded glucose infusion and continuing through the end of the 180-minute glucose infusion study period

Study Details

The purpose of this research is to understand how the function of the human pancreas changes during and after pregnancy.

Key Dates

First listed
Sep 8, 2026
Start date
Sep 30, 2026
Status verified
Sep 2026
Primary completion
Mar 31, 2030
Completion
Dec 31, 2030

Study Design

Enrollment
90 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Women With Gestational Diabetes Mellitus
    Pregnant participants diagnosed with gestational diabetes mellitus who complete pregnancy and postpartum metabolic study visits.
  • Experimental: Women Without Gestational Diabetes Mellitus
    Pregnant participants without gestational diabetes mellitus, matched to the gestational diabetes group by parity, age, ethnicity, gestational week at diagnosis comparator timepoint, and first trimester body mass index.

Primary Outcome Measure

G50 [ Time Frame: During pregnancy at approximately 26 to 32 weeks gestation and during the postpartum period at approximately 6 weeks to 3 months after delivery. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo ClinicRochesterMinnesota55905
Jeanette Laugen
507-255-8110
Amy Zipse
507-255-9278

Find similar trials in Rochester, MN

By research site
Mayo Clinic· Rochester, MN

Related Studies